State of Alaska Department of Revenue raised its position in shares of Boston Scientific Corporation by 22.5% during the 2nd quarter. As of quarter end Amalgamated Bank had acquired a total of 3,580 shares growing its holdings by 2.2%. Amalgamated Bank expanded its investment by buying 3,580 shares an increase of 2.2% as of 09/30/2017. American International Group Inc trimmed its stake by selling 21,527 shares a decrease of 5.0% as of 09/30/2017. Creative Planning now owns 42,540 shares of the medical equipment provider's stock worth $1,179,000 after purchasing an additional 2,234 shares during the last quarter. Over a month, it has seen its stock price volatility to stay at 1.65% while shortening the period to a week, volatility was 1.6%. Analysts are turning out to be more optimistic than before, with 18 of analysts who cover Boston Scientific Corporation (NYSE:BSX) advice adding it to buy candidate list. Winslow Capital Management LLC now owns 11,212,783 shares of the medical equipment provider's stock valued at $310,818,000 after buying an additional 2,011,640 shares during the period. "Reduces Position in Boston Scientific Corporation (NYSE:BSX)" was first posted by StockNewsTimes and is owned by of StockNewsTimes. Royal Bank Of Canada restated a "buy" rating and issued a $31.00 price target on shares of Boston Scientific Corporation in a research note on Friday, September 1st. Zacks Investment Research downgraded Boston Scientific Corporation from a "buy" rating to a "hold" rating in a research note on Monday, October 30th. Cowen and Company reissued a "buy" rating and issued a $32.00 target price (up previously from $31.00) on shares of Boston Scientific Corporation in a research report on Friday, July 28th. Finally, Canaccord Genuity initiated coverage on shares of Boston Scientific Corporation in a research report on Tuesday, October 24th. They issued a "buy" rating and a $36.00 price objective for the company.
A number of equities research analysts recently issued reports on BSX shares.
On October 13 BMO Capital Markets held the company rating at "Buy" targeting a price of $30.00.
Shares of Boston Scientific Corporation (BSX) traded down $0.19 during midday trading on Tuesday, reaching $28.26. The firm has a market cap of $38,943.84, a PE ratio of 23.25, a PEG ratio of 2.19 and a beta of 1.00. The quick ratio, on the other hand, is 0.5 indicating the company's current short-term liquidity.
Boston Scientific Corporation (NYSE:BSX) last posted its quarterly earnings results on Thursday, October 26th. As of the latest earnings report the EPS was $0.61 with 1.37B shares now outstanding. The firm had revenue of $2.22 billion during the quarter, compared to analysts' expectations of $2.21 billion.
Price-to-free-cash-flow (P/FCF) of 49.29 gives an overview of the equity valuation for Boston Scientific Corporation. The company's revenue for the quarter was up 5.6% compared to the same quarter previous year. The value in dollars went from $4,476,000 to $4,814,000 a change of 7.6% for the reporting period. The stock was sold at an average price of $28.22, for a total transaction of $282,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Sell-side analyst recommendations point to a short term price target of $28.4 on the company shares. Following the sale, the executive vice president now directly owns 185,742 shares of the company's stock, valued at $5,100,475.32. 4,722,300 shares of the company were exchanged, compared to its average volume of 6,640,035. 0 analysts gave its stock an Outperform rating. If you are reading this piece on another domain, it was stolen and reposted in violation of USA and worldwide trademark and copyright law.
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.